| 10/10/20 | FBIO | IV Tramadol (NDA) | FDA decision on IV Tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting |
| 10/10/20 | ATXI | IV Tramadol (NDA) | FDA decision on IV Tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting |
| 10/10/20 | ATXI | Intravenous tramadol (NDA) | FDA decision on IV tramadol for severe pain in adults following abdominoplasty surgery |
| 09/30/20 | MESO | Ryoncil (BLA) | FDA decision on Ryoncil for the treatment of children with steroid-refractory acute graft versus host disease |
| 09/29/20 | DNLM.L | Alkindi (NDA) | FDA decision on Alkindi Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents |
| 09/29/20 | ETON | Alkindi Sprinkle(NDA) | FDA decision on Alkindi Sprinkle for pediatric adrenal insufficiency, incl congenital adrenal hyperplasia in patients less than 17 years |